Erratum: Editor’s Note: Oncogenic Ras Promotes Reovirus Spread by Suppressing IFNb Production through Negative Regulation of RIG-I Signaling (Cancer Res (2010) 70 (4912–4921) DOI: 10.1158/0008-5472.CAN-09-4676);Oncogenic Ras promotes reovirus spread by suppressing IFN-β production through negative regulation of RIG-I signaling

Cancer Research

Volumn 70, Issue 12, 2010, Pages 4912-4921

  Shmulevitz, Maya ^a   Pan, Lu Zhe ^a   Garant, Katy ^a   Pan, Da ^a   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; VIRUS RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CANCER CELL CULTURE; CELL STRAIN 3T3; CELL STRAIN HCT116; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REOVIRUS; REOVIRUS INFECTION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS TRANSMISSION; WILD TYPE;

EID: 77953768352     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-22-1586     Document Type: Erratum

References (29)

1. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
2. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-62.
3. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-701. (Pubitemid 34408491)
4. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641-52. (Pubitemid 34264314)
5. Alain T, Kim TS, Lun X, et al. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 2007;15:1512-21. (Pubitemid 47099308)
6. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PW. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007;15:1522-30. (Pubitemid 47099309)
7. Smakman N, van den Wollenberg DJ, Borel RI, Hoeben RC, Kranenburg O. Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. J Virol 2005;79:14981-5. (Pubitemid 41636297)
8. Smakman N, van den Wollenberg DJ, Elias SG, et al. KRAS(D13) promotes apoptosis of human colorectal tumor cells by Reovirus T3D and oxaliplatin but not by tumor necrosis factor-related apoptosisinducing ligand. Cancer Res 2006;66:5403-8.
9. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008;226:10-8.
10. Nakhaei P, Genin P, Civas A, Hiscott J. RIG-I-like receptors: sensing and responding toRNAvirus infection. Semin Immunol 2009;21:215-22.
11. Sadler AJ, Williams BR. Structure and function of the protein kinase R. Curr Top Microbiol Immunol 2007;316:253-92.
12. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778-809.
13. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5. (Pubitemid 30469434)
14. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anticancer agents. Cancer Cell 2003;4:263-75.
15. Thorne SH. Oncolytic vaccinia virus: from bedside to benchtop and back. Curr Opin Mol Ther 2008;10:387-92.
16. Kirn DH, Wang Y, Le BF, Bell J, Thorne SH. Targeting of interferon-β to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007;4:e353.
17. Rudd P, Lemay G. Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Rastransformed cells. J Gen Virol 2005;86:1489-97. (Pubitemid 40613268)
18. Mendez II, Hermann LL, Hazelton PR, Coombs KM. A comparative analysis of freon substitutes in the purification of reovirus and calicivirus. J Virol Methods 2000;90:59-67.
19. Bar-Sagi D. A Ras by any other name. Mol Cell Biol 2001;21:1441-3.
20. Battcock SM, Collier TW, Zu D, Hirasawa K. Negative regulation of the α interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 2006;80:4422-30.
21. Christian SL, Collier TW, Zu D, Licursi M, Hough CM, Hirasawa K. Activated Ras/MEK inhibits the antiviral response of α interferon by reducing STAT2 levels. J Virol 2009;83:6717-26.
22. Klampfer L, Huang J, Corner G, et al. Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 2003;278:46278-87. (Pubitemid 37452198)
23. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006;22: 561-9. (Pubitemid 43817607)
24. Cui S, Eisenacher K, Kirchhofer A, et al. The C-terminal regulatory domain is the RNA 5′-triphosphate sensor of RIG-I. Mol Cell 2008;29:169-79. (Pubitemid 351172822)
25. Bowie AG, Fitzgerald KA. RIG-I: tri-ing to discriminate between self and non-self RNA. Trends Immunol 2007;28:147-50.
26. Hornung V, Ellegast J, Kim S, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7.
27. Myong S, Cui S, Cornish PV, et al. Cytosolic viral sensor RIG-I is a 5′-triphosphate-dependent translocase on double-stranded RNA. Science 2009;323:1070-4.
28. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1-47.
29. Sherry B. Rotavirus and reovirus modulation of the interferon response. J Interferon Cytokine Res 2009;29:559-67.